OncLive - Bringing the Oncology Community Together

Home

Nurses

Urology

Targeted Therapies

Interactive

Meetings

OncLive TV

Blogs

Hennessy's Highlights

Publications

Conference Coverage

2012 ASCO Annual Meeting

Live coverage of the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.

Cover Story

New Therapies for Prostate Cancer:
The Practicalities

With four new agents approved in the last two years and two promising agents in the pipeline, therapy selection and potential outcomes are changing.

Interactive Publication

Bevacizumab Plus IFN in mRCC

Drs Ronald Bukowski and Thomas Hutson present an educational and interactive guide reviewing metastatic renal cell carcinoma.

Web Exclusive

Revised View Enhances Provenge Overall Survival Data

A further analysis of clinical trial data for sipuleucel-T suggests that it may have delivered a greater OS benefit than previously described.

OncLive TV - A Network of Your Peers

Dr. Concepcion Discusses Prostate Cancer Therapies

Dr. Markman on Long-Term Chemotherapy Side Effects

Mary Gullatte Discusses Cancer Genetic Counseling

Dr. Sieber on Managing Bone Health After ADT

>>> Click here for more videos

Latest Oncology Headlines

Targeting the PI3K/Akt/mTOR Pathway for Lymphoma

One of the major developments in cancer treatment in recent years has been the potential of drugs that target the oncogenic PI3K/Akt pathway and mTOR, a downstream effector of the pathway.

Oncology Live Targeted Therapy News > News

Analysts, Companies Highlight Key ASCO Research

Pharmaceutical industry analysts and companies have been weighing in on their selections for the most noteworthy research to be presented during the 2012 ASCO Annual Meeting.

Conferences > 2012 ASCO Annual Meeting

Dr. Rotkowitz on BRAF/MEK Combination Side Effects

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects

Conferences > 2012 ASCO Annual Meeting

Approval of Axitinib Adds Another Therapy Option for Metastatic RCC

Axitinib joins three other multi-tyrosine kinase inhibitors, two mTOR inhibitors, and an antiangiogenic therapy as available treatments for metastatic RCC.

Oncology Live Targeted Therapy News > News

>>> Click here for more articles

Oncology Resources

Editor's Corner

Andrew Pecora, MD
Oncology & Biotech News
Bending the Cost Curve and Here Come the Judge(s)

Maurie Markman, MD
OncologyLive
Taking the Long View: Imatinib Success Story Stands the Test of Time

Andre Goy, MD, MS
Contemporary Oncology
Personalized Medicine: A Promising Future in Oncology Practice

Lisa Schulmeister, RN, OCN
OncLive Nursing
Sugar Fueled Diets

>>>View the entire advisory board